BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//European Brain Council (EBC) - ECPv6.15.19//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:European Brain Council (EBC)
X-ORIGINAL-URL:https://www.braincouncil.eu
X-WR-CALDESC:Events for European Brain Council (EBC)
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:UTC
BEGIN:STANDARD
TZOFFSETFROM:+0000
TZOFFSETTO:+0000
TZNAME:UTC
DTSTART:20210101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=UTC:20221018T173000
DTEND;TZID=UTC:20221018T183000
DTSTAMP:20260415T002030
CREATED:20220916T084617Z
LAST-MODIFIED:20230224T095704Z
UID:40694-1666114200-1666117800@www.braincouncil.eu
SUMMARY:Rethinking the early detection and diagnosis of Alzheimer’s disease | Alzheimer Europe Conference
DESCRIPTION:Alzheimer’s disease (AD) is a major unmet medical need that requires innovation to be aligned with public health and health systems‘ needs. AD represents between 60 and%70% of the dementia cases. It is still diagnosed too late\, when the symptoms become more evident as the disease progresses. \nAD is now portrayed as a continuum consisting of three stages: an asymptomatic preclinical phase\, a mild cognitive impairment (MCI) phase\, and dementia. To match this continuum\, current research efforts are now focussing on the earlier stages of the disease (MCI stage)\, when it is believed that a therapeutical intervention at that stage would slow or prevent disease progression. \nThe speakers of the evening symposium “Rethinking the early detection and diagnosis of Alzheimer’s disease”\, set to take place on 18 October 2022 from 17:30-18:30 (Bucharest time) at the Alzheimer Europe Conference\, will present a research-driven project RETHINKING Alzheimer’s disease. The project is led by the European Brain Council (EBC) in collaboration with the European Federation of Pharmaceutical Industries and Associations (EFPIA) with the aim to identify the roadblocks to early detection and diagnosis of AD and will propose new clinical pathways building bridges between all stakeholders to improve the current situation and prepare for the future. \nSpeakers’ biographiesKevin Quaid\, Vice-Chairperson\, European Working Group of People with Dementia  \nLimerick native Kevin Quaid was diagnosed with Lewy Body Dementia in 2017 aged 53\, after being diagnosed firstly with Parkinsons. He is a member of the Irish Dementia Working Group as well as vice chair of the European Working Group of People with dementia and co founder of Lewy body Ireland  \nKevin is an avid GAA fan and speaks about the fighting spirit of the Limerick hurling team in 2018 and the fact they never gave up. He brings that same spirit to his life with dementia.  \nKevin is married to Helena. He has three children\, three stepchildren and five grandchildren. This family man is an adventurer who spent time in Australia and loves to travel.  \nAfter his diagnosis Kevin realised there was a lack of information about his particular form of dementia and wrote a book called “Lewy Body Dementia\, Survival and Me”. He was one of the first patients in the world to write a book about Lewy Body Dementia from the patients point of view as well as his families point of view\, He has since written a second book called “I am KEVIN not Lewy” . He is now an active advocate and through his work with the Irish Dementia Working Group supported by The Alzheimer Society of Ireland raises awareness about the condition through speaking engagements and media appearances. \nWiesje van der Flier\, Scientific Director\, Alzheimer Center Amsterdam  \nWiesje van der Flier (1975) is full professor and scientific director of Alzheimer center Amsterdam at Amsterdam UMC\, the Netherlands\, where she works since 2004. She studied neuropsychology at the University of Utrecht. In addition\, she is clinical epidemiologist. She leads the Amsterdam Dementia Cohort\, an ongoing memory-clinic based cohort including over 6000 patients with deep phenotyping (MRI\, EEG\, CSF biomarkers\, and PET) and linked biobank (blood\, DNA\, CSF). The Amsterdam Dementia Cohort is at the basis of many of the studies performed at Alzheimer center Amsterdam. Van der Flier has been (co)promotor of >20 theses and is currently supervising ~10 PhD projects. Van der Fliers main research areas are looking for the origin of AD\, diagnosis&prognosis\, and intervention&prevention. Van der Flier leads ABOARD (A Personalized Medicine Approach for Alzheimer's Disease)\, a Dutch public-private partnership of than 30 partners. Together with colleague Philip Scheltens\, she has written a book\, het Alzheimermysterie\, which was published by the Arbeiderspers.  \nLenka Krajčovičová\, Assistant Professor\, Masaryk University  \nLenka Krajčovičová has a PhD in neurology at Masaryk University in Brno (Czech Republic). Her scientific topics include neurodegenerative disorders – Parkinson´s disease and Alzheimer´s disease in particular\, movement disorders\, cognitive disorders.  \nShe has been involved in numerous research projects such as Microbiome in neurodegenerative diseases with cognitive impairment (Czech national recovery program)\, Diagnostics of Lewy body diseases in the prodromal stage based on multimodal data analysis\, supported by Ministry of Health of the Czech Republic\, Modulation of cognition and brain connectivity by noninvasive brain stimulation in patients with mild cognitive impairment due to Alzheimer's disease\, supported by Ministry of Health of the Czech Republic\, Effect of intensive dance-exercise intervention on cognitive function and changes of brain plasticity in healthy seniors and patients with mild cognitive impairment in early stage of Alzheimer´s disease\, supported by Ministry of Health of the Czech Republic and Pre-clinical genotype-phenotype predictors of Alzheimer´s disease and other dementia (APGeM)\, supported by EU Joint Program – Neurodegenerative Disease Research.   \nLenka Krajčovičová is a member of the Czech medical society\, the Czech neurological society\, the Section of cognitive neurology\, the Section of extrapyramidal neurology and the Czech society for clinical neurophysiology.    \nLydia Lanman\, Senior Global Policy Leader\, Roche  \nLydia Lanman is a senior Global Policy Leader at Hoffmann-La Roche and is responsible for leading Roche efforts across a variety of global health policy areas. Her area of expertise is in brain health and Alzheimer's disease.  \nLydia joined the pharmaceutical industry in Canada in 2007\, where she has led a variety of national policy\, government relations and market access efforts at two pharmaceutical firms. Prior to joining pharma\, Lydia worked in various senior advisory roles in Canada\, providing strategic advice directly to Ministers and Deputy Ministers of Health\, both federally and provincially\, on the development of health care policy\, health system design and intergovernmental relations.  \nLydia holds a Bachelor of Arts in Political Science and a Master of Arts in Political Science and Public Health\, both from the University of Alberta. Her graduate work focused primarily on Canadian and international health care reforms. \nFor privacy reasons YouTube needs your permission to be loaded. For more details\, please see our Privacy Policy.I Accept
URL:https://www.braincouncil.eu/event/alzheimer-europe-conference-rethinking-the-early-detection-and-diagnosis-of-alzheimers-disease/
LOCATION:Bucharest\, Romania
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20221017T111500
DTEND;TZID=UTC:20221017T120000
DTSTAMP:20260415T002030
CREATED:20220506T115240Z
LAST-MODIFIED:20221017T074652Z
UID:36340-1666005300-1666008000@www.braincouncil.eu
SUMMARY:The value of early intervention and continuity of care for mental disorders | ECNP Congress
DESCRIPTION:Mood Disorders are a common\, chronic\, severe\, complex and costly group of predominantly recurrent psychiatric illness that can be devastating for the affected individual and their families and impose a high health care related burden. Major depressive disorder and bipolar disorder are the main diagnostic categories in mood disorders. There is a significant clinical need for more effective detection and better delivered treatments for these illnesses. Major depressive disorder accounts for the predominant burden associated with both unipolar and bipolar disorder. However\, both the identification and management of bipolar depression are more challenging\, since bipolar depression differs little symptomatically from unipolar depression and responds poorly to traditional antidepressants\, which may also induce a switch to mania and/or cause rapid cycling. The physical health of people with all mood disorders is compromised and their life expectancy markedly reduced. The aim of a care pathway is to enhance quality of care by improving patient outcomes\, promoting patient safety\, increasing patient satisfaction\, and optimizing the use of resources. \nWith this in mind\, the European Brain Council (EBC) initiated in 2019 a study called the Value of Treatment (VoT) to address diagnostic and treatment gaps for brain (including mental and neurological) disorders. The EBC deemed it necessary to add case studies on mental health conditions such as major depressive disorder and autism. Disease treatment pathways should run from detection in the community through primary and secondary care to specialist clinics. Early intervention and continuity of care are very necessary to effectively manage patients’ mood disorders and overall health.
URL:https://www.braincouncil.eu/event/the-value-of-early-intervention-and-continuity-of-care-for-mental-disorders-ecnp-congress/
LOCATION:Vienna\, Austria
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221016
DTEND;VALUE=DATE:20221021
DTSTAMP:20260415T002030
CREATED:20220427T135333Z
LAST-MODIFIED:20221103T084552Z
UID:36088-1665878400-1666310399@www.braincouncil.eu
SUMMARY:European Congress of Neurosurgery 2022
DESCRIPTION:The European Congress of Neurosurgery 2022 (EANS2022) took place on 16-20 October in Belgrade\, Serbia. The European Association of Neurosurgical Societies (EANS) is both an independent federation of European national neurosurgical societies and a fast-developing association of individual neurosurgeons from around the world. \nThe Congress theme – Trends\, Insights\, Innovations: Neurosurgery beyond Technology – addressed the complex relation between technological advances and human ingenuity in the field of neurosurgery. The age of rapid technological progress\, artificial intelligence\, machine learning and virtual reality in the 21st century has brought many benefits to neurosurgery\, but also many challenges. \nAfter two turbulent pandemic years\, the Congress in Belgrade represented the regathering of European and world experts in neurosurgery. It provided an excellent opportunity for sharing experiences and exchanging ideas through the top-level scientific program\, aimed at providing a comprehensive insight into these benefits and challenges and striking the right balance between technology and human (neurosurgeons’) touch. \nEBC President\, Prof. Wolfgang Oertel\, was pleased to take part in the congress and present “EBC and the Brain Policies in Europe” during a plenary “Brain & Spine\, The Official Journal of EANS & EUROSPINE” on 19 October 2022 at 13:50-14:30. \nFind more information on the congress here.
URL:https://www.braincouncil.eu/event/european-congress-of-neurosurgery-2022/
LOCATION:Belgrade\, Serbia
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221015
DTEND;VALUE=DATE:20221019
DTSTAMP:20260415T002030
CREATED:20211116T141423Z
LAST-MODIFIED:20221026T122923Z
UID:32607-1665792000-1666137599@www.braincouncil.eu
SUMMARY:EBC at the 35th European College of Neuropsychopharmacology (ECNP) Congress
DESCRIPTION:The annual European College of Neuropsychopharmacology (ECNP) Congress is Europe’s premier scientific meeting for disease-oriented brain research\, annually attracting more than 5\,000 psychiatrists\, neuroscientists\, neurologists and psychologists from around the world. \nThe European College of Neuropsychopharmacology (ECNP) is an independent scientific association dedicated to the science and treatment of disorders of the brain. It is the largest non-institutional supporter of applied and translational neuroscience research and education in Europe. \nEBC was pleased to take part in the ECNP Congress which took place on 15-18 October 2022 in Vienna (Austria) and virtually. Alongside an Exhibition Stand in the exhibition area (booth 16)\, EBC had a campfire session The value of early intervention and continuity of care for mental disorders take place on 17 October at 11:15 – 12:00. The session\, moderated by Prof. Judit Simon\, featured the following presentations: \n\nThe value of early intervention for associated epilepsy in autism by Prof. Celso Arango\, Spain\nThe value of early intervention and continuity of care for mood disorders by Prof. Allan Young\, United Kingdom\n\nAdditionally\, the EBC project the European Brain Research Area (EBRA) was showcased at the congress through a poster. \nWe look forward to the next year’s congress which will take place from 7-10 October 2023 in Barcelona (Spain)!
URL:https://www.braincouncil.eu/event/35th-ecnp-congress/
LOCATION:Vienna\, Austria
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20221011T080000
DTEND;TZID=UTC:20221011T140000
DTSTAMP:20260415T002030
CREATED:20220328T093117Z
LAST-MODIFIED:20220804T122055Z
UID:35183-1665475200-1665496800@www.braincouncil.eu
SUMMARY:European Brain Research Area Final Conference
DESCRIPTION:  \nThe European Brain Research Area (EBRA) project partners are delighted to invite you to the upcoming Final Conference\, which will take place on 11 October 2022 in Brussels\, Belgium. \n\n\n\nFour years have already passed and plenty of work is to be presented this coming October\, including the EBRA Landscape Analysis\, the Shared European Brain Research Agenda (SEBRA) as well as the work undertaken by the six EBRA Clusters. The event will be an occasion to bring the wider brain research community and key players together\, to discuss key aims of the project: the current state of brain research in Europe\, increased patient engagement and public awareness\, research infrastructures and data sharing and the future potentials and need for a brain health partnership going forward. \nCollaboration and cooperation in the brain research area remain more important than ever and the EBRA Final Conference will be a major milestone to ensure unification and commitment to the future of brain research in Europe. \nThe EBRA Final Conference will be held in conjunction with the Brain Innovation Days\, taking place on 11-12 October 2022 in Brussels. \nDiscover the programme and register here.
URL:https://www.braincouncil.eu/event/european-brain-research-area-final-conference/
LOCATION:Brussels\, Belgium
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221011
DTEND;VALUE=DATE:20221013
DTSTAMP:20260415T002030
CREATED:20220325T132157Z
LAST-MODIFIED:20220804T122043Z
UID:35134-1665446400-1665619199@www.braincouncil.eu
SUMMARY:Brain Innovation Days: Connecting Brains
DESCRIPTION:  \nThis year’s Brain Innovation Days event will centre around Connecting Brains; bringing together the current and future generations of brain research and innovation.  \n\n\n\nThe focus of the 2022 event will be to enable space and opportunity for open discussion and showcasing\, prioritising matchmaking and networking within the community\, particularly of stakeholders who may not have the opportunity to connect in their day-to-day. \n\n\n\n\n\n\nPre-event matchmaking would be encouraged through a dedicated platform in order to facilitate interaction on the day and programme details will be shared between March and May 2022 in order to attract a wider audience and kickstart networking opportunities.  \n\n\n\n\n\n\nThe 2nd Brain Innovation Days Pitch Competition will take place on the day\, with five pre-selected finalists battling live for the jury and public prizes for Best Pitch \n\n\n\n\n\n\nAn Innovation Corner will be set up for companies to showcase their tangible tools and devices and for researchers to present posters\, an area that will be open on the 11th in the afternoon during the EBRA Final Conference and throughout the day on the 12th and host a guided tour during the Networking Reception on 12 October.  \n\n\n\n\n\n\nThe day will host a series of How-To sessions focused on business and networking skills\, a high-level investor panel\, a policy-focused roundtable discussion on research funding\, countless networking opportunities (both in groups and one-on-one) and exciting Brain Talks. \nA pre-event\, 12-episode season 2 of the Brain Talks podcast series will follow the chosen theme of the 2022 BIDs\, also involving members of EBC\, pulling in the perspective of scientists\, clinicians\, patients and more.  \nDiscover the programme and register here!
URL:https://www.braincouncil.eu/event/brain-innovation-days-connecting-brains/
LOCATION:Brussels\, Belgium
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221007
DTEND;VALUE=DATE:20221010
DTSTAMP:20260415T002030
CREATED:20220927T134839Z
LAST-MODIFIED:20220927T134839Z
UID:40974-1665100800-1665359999@www.braincouncil.eu
SUMMARY:13th International Autism-Europe Congress
DESCRIPTION:The 13th International Autism-Europe Congress is the first full online Congress with high quality access to its sessions\, presentations\, workshops\, discussion panels and more. You can join in person as well\, in the historical city of Cracow. The Congress brings expertise from around the world to promote a positive vision for autistic people and their families. \n“Happy Journey through Life” is the theme of the Congress – to highlight the importance of taking a lifespan perspective on autism research and practice\, with the promotion of wellbeing for all being the focal point. \nEBC looks forward to presenting the following sessions: \n\nThe value of treatment study: Autism care pathway in Europe (7 October\, 17:00-18:00; Oral Session)\n\nAutism is a lifelong complex neurodevelopmental condition of early onset that affects brain development and behaviour\, characterised by difficulties in social communication\, restricted and repetitive patterns of behaviour\, interests or activities\, and sensory issues which have significant consequences in daily life.  \nThe Value of Treatment (VOT) study results on autism care pathway in Europe will be presented. Early intervention can play a crucial role in the earlier social-communicative and emotional development which will act as a bridge for other more complex abilities. The primary goal of early intervention is to maximize functional independence and quality of life. Despite its great societal and personal impact\, Europe-wide consensus and support for early detection\, diagnosis\, and intervention of autism are lacking.   \n\nAutism with associated epilepsy care pathway in Europe (8 October\, 9:00-13:00; Poster Presentation)\n\nAutism and epilepsy are frequently associated. The prevalence of epilepsy in autism is greater than in the general population. Electroencephalography (EEG) has been used to investigate epilepsy in autism. EEGs are recommended if there is clinical suspicion of epilepsy. However\, the clinical identification of seizures in autism can be challenging because some of the features of seizures such as staring spells\, non-responsiveness and repetitive motor behaviours are also manifestations of autism.  \nAssociated conditions in autism such as epilepsy have a substantial impact on the well being of autistic people and their families\, contribute to reduced quality of life and may increase premature mortality. Despite this\, there is a current lack of studies assessing the journey experienced by autistic children with co-occurring epilepsy and their families in Europe. The VOT study on Autism with associated epilepsy care pathway in Europe will be presented. 
URL:https://www.braincouncil.eu/event/13th-international-autism-europe-congress/
LOCATION:Krakow\, Poland
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20220926T120000
DTEND;TZID=UTC:20220926T190000
DTSTAMP:20260415T002030
CREATED:20220914T133155Z
LAST-MODIFIED:20220921T131538Z
UID:40645-1664193600-1664218800@www.braincouncil.eu
SUMMARY:Global Partnerships in Brain Research Event at Science Summit @ UNGA77
DESCRIPTION:In the framework of the Science Summit at the 77th United Nations General Assembly\, the European Brain Council and Cohen Veterans Bioscience\, in partnership with the Brain Capital Alliance and OECD Neuroscience-inspired Policy Initiative are pleased to convene a meeting on Global Partnerships in Brain Research with leaders in neuroscience\, to highlight existing global partnerships and explore collaboration and alignment for the future. \nPlease see the details\, programme and list of attendees below. Want more information or are you interested in joining us in New York? Please email EBC’s Head of Communications\, Advocacy and Policy\, Stephanie Kramer via stkr@braincouncil.eu \nGlobal Research Collaboration Event - Details and Attendees - SSUNGA77
URL:https://www.braincouncil.eu/event/global-partnerships-in-brain-research-event-at-science-summit-unga77/
ATTACH;FMTTYPE=image/jpeg:https://www.braincouncil.eu/wp-content/uploads/2022/09/Blank-Template-Twitter-Post-2-scaled.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220904
DTEND;VALUE=DATE:20220909
DTSTAMP:20260415T002030
CREATED:20211116T143551Z
LAST-MODIFIED:20211116T143551Z
UID:32618-1662249600-1662681599@www.braincouncil.eu
SUMMARY:32nd International Congress of Clinical Neurophysiology
DESCRIPTION:  \nThe International Federation of Clinical Neurophysiology along with the Swiss Society of Clinical Neurophysiology are pleased to announce the 32nd International Congress of Clinical Neurophysiology (ICCN) will be held September 4–8\, 2022 in Geneva\, Switzerland. The ICCN 2022 program will include several signature courses\, as well as symposia and workshops planned by IFCN Member Societies and other prominent societies in clinical neurophysiology from Europe and around the world. Pre-Congress courses and workshops are designed to provide a solid review of the fundamentals and the latest scientific advances in both central and peripheral clinical neurophysiology. Three days of general and concurrent Congress sessions will include honorary lectures\, symposia\, workshops\, controversies sessions\, and industry-supported satellite symposia. The IFCN and SSCN look forward to welcoming colleagues to Geneva! \nVisit the congress website for more info!
URL:https://www.braincouncil.eu/event/32nd-international-congress-of-clinical-neurophysiology/
LOCATION:Geneva\, Switzerland
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20220831T200000
DTEND;TZID=UTC:20220831T210000
DTSTAMP:20260415T002030
CREATED:20220823T084727Z
LAST-MODIFIED:20220823T084727Z
UID:39954-1661976000-1661979600@www.braincouncil.eu
SUMMARY:Overcoming roadblocks: Making psychedelic-assisted therapy a reality
DESCRIPTION:Learn about when and how psychedelic-assisted therapy becomes a reality. What are the legislative and regulatory roadblocks\, and how Chris Koddermann (ITPRI – Reschedule Psilocybin)\, Amy Emerson (MAPS PBC)\, Tadeusz Hawrot (PAREA – Psychedelic Access and Research European Alliance) and Graham Pechenik (Calyx Law) are taking them down? When will psychedelic-assisted therapy become a reality in Europe and the US? \nCurious to learn more? Register here.
URL:https://www.braincouncil.eu/event/overcoming-roadblocks-making-psychedelic-assisted-therapy-a-reality/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20220712T184500
DTEND;TZID=UTC:20220712T200000
DTSTAMP:20260415T002030
CREATED:20220131T110232Z
LAST-MODIFIED:20220705T100151Z
UID:33891-1657651500-1657656000@www.braincouncil.eu
SUMMARY:Brain capital and the young generation
DESCRIPTION:FENS Forum 2022 – Special Interest Session & Networking Event: “Brain capital and the young generation”  \nTuesday 12 July 2022 at 18:45-20:30\, Hall G \nSession moderated by FENS President\, Prof. Jean Antoine Girault\, and EBC President\, Prof. Wolfgang Oertel \n  \nMental health disorders cannot be ignored\, nor can their devastating impact on families\, communities\, and lives. The cost of not acting is tremendous. There is a need to improve the efficiency of brain health and care pathways\, prevent avoidable deaths and implement cost-effective solutions.   \nYouth is the future. However\, recent studies underscore the severity of the mental health challenges children and adolescents face that can lead to disability\, disease\, and death. There are numerous unmet needs along the care pathway\, although effective early detection and interventions exist. Navigating the mental health services system is often complex for families\, due to services that are fragmented or disrupted. According to the OECD (2018)\, the total costs of mental ill-health are estimated at more than 4% of GDP – or over 600 billion€ – across the 28 EU countries. And the burden is increasing. The Covid-19 pandemics exacerbated the situation. Policies and programmes to prevent and mitigate the negative impacts on schooling\, employment\, mental health\, and risky behaviors are therefore paramount. The accumulation of human and social capital must start at a young age as the brain develops rapidly during early childhood and adolescence. Moreover\, early cognitive\, and non-cognitive skills and health capabilities lead to enhanced effectiveness of later investment.   \nAs a result\, by building a strong foundation\, investing in optimal interventions tailored to the young generation advances socio-economic development. The EBC and FENS – in collaboration with the OECD\, UNESCO\, WHO – will convene a meeting at the FENS Forum 2022 in Paris\, France to address these challenges.   \n  \n\n\n\nTopic \nSpeaker \nApproximate time \n\n\nIntroduction : neuroscience and brain development \nProf. Jean Antoine Girault\, FENS President \n5 mins \n\n\nEBC Brain Health Definition: overview challenges  \nProf. Wolfgang Oertel\, EBC President \n5 mins \n\n\nBrain capital: accelerating responsible innovation \nProf. Harris Eyre\, Co-Founder of the PRODEO Institute and Co-Lead of the OECD Neuroscience-inspired Policy Initiative \n10 mins \n\n\nEBC Joint Value of Treatment Study on Mental Disorders \nMs Vinciane Quoidbach\, EBC Research project manager \n5 mins \n\n\nAnorexia Nervosa care pathway  \nin Europe \nProf. Philip Gorwood\, Hôpital Sainte-Anne\, GHU Paris Psychiatrie et Neurosciences\, Université de Paris\, France \n5 mins \n\n\nAutism in children: economic analysis of promising interventions \nDr Michela Tinelli\, London School of Economics\, United Kingdom  \n5 mins \n\n\nCare pathways for people with  \nmajor depressive disorder \nProf. Allan Young\, Institute of Psychiatry\, Psychology & Neuroscience\, King’s College London\, United Kingdom \n5 mins \n\n\nPrecision psychiatry \nDr. Joachim Scholpp\, Global Head of Translation Medicine CNS & Emerging Areas\, Boehringer Ingelheim \n5 mins \n\n\nMental disorders and youth\, a WHO perspective \nDr Ledia Lazeri\, Regional Advisor for Mental Health at WHO Regional Office for Europe  \n5 mins \n\n\nEducation and the brain \nDr Anna Cristina d’Addio\, Senior Policy Analyst (Thematic Lead)  \nGlobal Education Monitoring Report\, UNESCO  \n5 mins  \n\n\nWrapping-up  \nDr William Hynes\, Head of the New Approaches to Economic Challenges Unit (NAEC)\, OECD  \n5 min \n\n\nDiscussion moderated by Prof. Jean Antoine Girault\, FENS President and Prof. Wolfgang Oertel EBC President (30’) \n\n\nReception (30’) \n\n\n\n   \nFor more information on the Value of Treatment project: The Value of Treatment project on mental disorders have just released summaries of case study results and call to action on the occasion of Brain Awareness Week 2022 – Thematic: #Together4MentalHealth with a focus on youth\, visit https://www.braincouncil.eu/value-of-treatment-project-releases-first-results-and-calls-to-action-on-the-occasion-of-brain-awareness-week-2022/ 
URL:https://www.braincouncil.eu/event/brain-capital-and-the-young-generation/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20220711T120000
DTEND;TZID=UTC:20220711T124500
DTSTAMP:20260415T002030
CREATED:20220117T130737Z
LAST-MODIFIED:20220705T090930Z
UID:33686-1657540800-1657543500@www.braincouncil.eu
SUMMARY:The European Brain Research area: Building a Brain Health Partnership
DESCRIPTION:The European Brain Research Area (EBRA) will host a Special Interest Event at the upcoming FENS Forum 2022 on 11 July at 12:00-12:45 in Hall B. \nBrain research is a rapidly evolving field and increasingly at the forefront of science. The EU and its Member States have made considerable investment in brain research leading to a significant increase of initiatives in this area. Although these initiatives have generated considerable amounts of knowledge and innovative approaches\, the translation into new health interventions is hindered by the complexity of the challenge and by excessive fragmentation of efforts. Effective and efficient collaboration among the various initiatives is often identified as a key success factor to achieve the full impact of brain research. The European Brain Research Area project therefore aims to bring together the various stakeholders and major brain research initiatives\, at European level and beyond\, creating the conditions for real and effective cross fertilisation\, dialogue\, building consensus and exploiting research potential. \nDuring this special session\, the EBRA consortium — consisting of the European Brain Council\, the ERANET-NEURON\, the EU Joint Programme for Neurodegenerative Disease Research and the Human Brain Project — will highlight the importance of shaping the future of European and globally coordinated neuroscience.  In this perspective\, the Shared European Brain Research Agenda (SEBRA) will be presented\, and discussion will focus on the building of a new partnership on brain health. \n  \nAgenda \n12:00-12:05:        Introduction to the European Brain Research Area \n                               Frédéric Destrebecq\, European Brain Council \n12:05-12:15:        The Shared European Brain Research Agenda \n                               Kristien Aarts\, European Brain Council \n12-15 – 12:45:    Panel discussion with the EBRA partners \n                                Philippe Amouyel\, JPND \n                                Marlies Dorlöchter\, ERANET-NEURON \n                                Pawel Swieboda\, HBP \n                                Juan Lerma\, European Brain Council \n  \n 
URL:https://www.braincouncil.eu/event/ebra-session-at-fens-forum-2022/
LOCATION:Paris Expo Porte de Versailles\, Pavillon 7\, Hall B
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20220710T143000
DTEND;TZID=UTC:20220710T154500
DTSTAMP:20260415T002030
CREATED:20220701T111624Z
LAST-MODIFIED:20220708T133951Z
UID:37947-1657463400-1657467900@www.braincouncil.eu
SUMMARY:FENS Forum 2022 Advocacy Training Workshop
DESCRIPTION:We are delighted to invite you to the FENS Forum 2022 Advocacy Training Workshop ⁠— a hands-on advocacy workshop for FENS National Societies and National Brain Councils ⁠— taking place on Sunday\, 10 July 2022\, from 14:30-15:45 in Hall I (level 7.3). \nFeatured speakers will include Jean-Antoine Girault (FENS President)\, Kirk Leech (Executive Director\, European Animal Research Association) and Frédéric Destrebecq (Executive Director\, European Brain Council). The training will include group discussion and serve to bring together National Brain Councils and FENS member societies to share experiences\, voice advocacy needs and encourage more coordinated promotion and advocacy for brain research and health in Europe. \nIf interested\, please register here: https://form.jotform.com/221661977728368
URL:https://www.braincouncil.eu/event/fens-forum-2022-advocacy-training-session/
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220709
DTEND;VALUE=DATE:20220714
DTSTAMP:20260415T002030
CREATED:20211116T140518Z
LAST-MODIFIED:20211116T140727Z
UID:32599-1657324800-1657756799@www.braincouncil.eu
SUMMARY:FENS Forum 2022
DESCRIPTION:The FENS Forum is Europe’s largest international neuroscience conference\, covering all domains in modern brain research from basic to translational research. \nThe Forum represents a unique opportunity for neuroscientists from around the world to gather together and enjoy excellent science in one of Europe’s most vibrant cities. \nOrganised by FENS in partnership with the French Neuroscience Society\, the FENS Forum 2022 will take place on 9-13 July 2022 in Paris\, France. \nThe FENS Forum 2022 will bring together experts in all fields of neuroscience to take us to the forefront of our current understanding of modern brain science. Visit the Forum 2022 website to meet the plenary and special lecturers!
URL:https://www.braincouncil.eu/event/fens-forum/
LOCATION:Paris\, France
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220704
DTEND;VALUE=DATE:20220709
DTSTAMP:20260415T002030
CREATED:20220120T091348Z
LAST-MODIFIED:20220121T143549Z
UID:33746-1656892800-1657324799@www.braincouncil.eu
SUMMARY:XVI Workshop on Neurobiology of Epilepsy (WONOEP 2022)
DESCRIPTION:WONOEP XVI\, a satellite event of the 14th ILAE European Epilepsy Congress\, will take place at Talloires\, France. The main topic of WONOEP XVI is “Early onset epilepsies: neurobiology and novel therapeutic strategies”. The overall purpose of WONOEP XVI will be to provide novel insights on early onset epilepsies\, underlying neurobiology and strategies towards the development of new treatments. \nMore information here: https://bit.ly/3fEB91R
URL:https://www.braincouncil.eu/event/xvi-workshop-on-neurobiology-of-epilepsy-wonoep-2022/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20220627T140000
DTEND;TZID=UTC:20220701T173000
DTSTAMP:20260415T002030
CREATED:20220408T084448Z
LAST-MODIFIED:20220408T085256Z
UID:35467-1656338400-1656696600@www.braincouncil.eu
SUMMARY:11th European Conference on Rare Diseases & Orphan Products
DESCRIPTION:The European Conference on Rare Diseases & Orphan Products (ECRD) is recognised globally as the largest\, patient-led rare disease event in which collaborative dialogue\, learning and conversation takes place\, forming the groundwork to shape goal-driven rare disease policies and allow for important and innovative discussions on a national and an international level to take place. ECRD 2022 will take place online on 27 June -1 July. \nLeading\, inspiring and engaging all stakeholders to take action\, the Conference is an unrivalled opportunity to network and exchange invaluable knowledge with over 1500 stakeholders in the rare disease community – patient advocates\, policy makers\, researchers\, clinicians\, healthcare professionals\, healthcare industry representatives\, academics\, payers\, regulators and Member State representatives. \nEBC is pleased to take part in the 2022 ECRD as an Associate Partner. \nFind out all the conference details – including programme – through the official website. Registration for the conference is open and the deadline for Poster Submissions has been extended until 21 April. \n 
URL:https://www.braincouncil.eu/event/11th-european-conference-on-rare-diseases-orphan-products/
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220625
DTEND;VALUE=DATE:20220629
DTSTAMP:20260415T002030
CREATED:20220318T155450Z
LAST-MODIFIED:20220701T114040Z
UID:34944-1656115200-1656460799@www.braincouncil.eu
SUMMARY:EBC at EAN Congress 2022
DESCRIPTION:EBC was pleased to be part of this year’s Congress of the European Academy of Neurology\, which took place in person on 25-28 June 2022 in Vienna\, Austria. Alongside an Exhibition Stand in the EAN Neurohood\, EBC had a Special Session take place on 28 June at 13:00-14:30 (Room Berlin)\, celebrating 20 Years of Advocacy for the Brain. The session featured the following presentations: \nIntroduction & Moderation by Prof. Wolfgang Oertel\, President\, European Brain Council\nHistory of the European Brain Council by Prof. Jes Olesen\, Founding President\, European Brain Council\nInvolving patients and the Value of Treatment by Joke Jaarsma\, Treasurer\, European Brain Council and President\, European Federation of Neurological Associations\nAdvocating for the brain: the European Brain Research Area by Frédéric Destrebecq\, Executive Director\, European Brain Council \n  \n  \n\n		\n		\n			\n				\n			\n				\n				EBC President\, Prof Wolfgang Oertel\, gives introductory presentation on EBC and to key moments in its 20-year history\n				\n			\n				\n			\n				\n				EBC Treasurer\, Joke Jaarsma\, reflects on 20 years of partnership between EBC and the European Federation of Neurological Associations\, a key member of EBC and patient representatives in the field of neurology.\n				\n			\n				\n			\n				\n				Prof Jes Olesen\, Founding President of EBC\, looks back on the last 20 years and the growth of the organisation since its humble beginnings.\n				\n			\n				\n			\n				\n				EBC Executive Director\, Frédéric Destrebecq\, provides insight on the important advocacy work done by EBC to culminate in its latest large-scale project\, the European Brain Research Area (EBRA)\n				\n		\n\n  \n  \nAdditionally\, EBC projects such as the European Brain Research Area (EBRA) and the Value of Treatment were showcased at the congress in the Scientific Theatre and through ePosters. \nScientific Theatres:\n– EBC Value of Treatment (VOT) Study – Bridging gaps and achieving seamless\, coordinated care\, a study on rare neurological and neurometabolic disorders by the European Brain Council – 25 June 2022\, 14:00 – 14:30 (Theatre 09)\n– EBC Value of Treatment (VOT) Study – A Comparison of Optimal Management vs Current Management of Chronic Pain– 27 June 2022\, 10:00-10:30 (Theatre 25)\n– European Brain Research Area (EBRA): Outcome and results of the Horizon 2020 project – 28 June 2022\, 10:30-11:00 (Theatre 37)\n \nePosters:\n– EBC Value of Treatment (VOT) Study – A Comparison of Optimal Management vs Current Management of Chronic Pain – 26 June 2022\, 12:30 to 13:15 (Screen B7)\n– EBC Value of Treatment (VOT) Study – Assessing the Value of Specialist Centres for the Diagnosis and Management of the Ataxias in Europe – 26 June 2022\, 12.30-13.15 (Screen A9) \n  \n  \n\n		\n		\n			\n				\n			\n				\n				Vinciane Quoidbach\, EBC Research Project Manager\, presents the Value of Treatment – Chronic Pain study at the Scientific Theatre\n				\n			\n				\n			\n				\n				Views of the congress space\n				\n			\n				\n			\n				\n				Prof Paola Giunti presents the Value of Treatment Ataxia study at the Scientific Theatre\n				\n			\n				\n			\n				\n				EBC Staff in the Neurohood\n				\n			\n				\n			\n				\n				EBC Project Manager\, Dr Kristien Aarts\, presents the European Brain Research Area (EBRA) project at the Scientific Theatre
URL:https://www.braincouncil.eu/event/ebc-at-ean-congress-2022/
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220625
DTEND;VALUE=DATE:20220629
DTSTAMP:20260415T002030
CREATED:20211115T145110Z
LAST-MODIFIED:20211116T140619Z
UID:32492-1656115200-1656460799@www.braincouncil.eu
SUMMARY:8th Congress of the European Academy of Neurology
DESCRIPTION:  \nThe 8th Congress of the European Academy of Neurology (EAN) will take place in Vienna (Austria) on June 25 to 28\, 2022. \nOur ambition is that the 8th EAN Congress will be a truly pan-European meeting\, in a fact the premier meeting of 2022\, bringing together neurologists and neuro-scientists to network and to exchange knowledge to tackle major challenges in neurology. In previous years EAN congresses have highlighted the developments in the host nation\, but in 2022\, following virtual congresses in 2020 and 2021\, we will break with that tradition. We have planned a meeting with a pan-European flavor\, celebrating the opportunity to meet once more in person in a hybrid meeting that will also maximise virtual participation\, building on our experience in 2020 and 2021. \nOur common European cultural heritage is rooted in innumerable domains: art\, architecture\, film\, philosophy\, literature\, and music to name a few. From a historical perspective\, we also know that great strides in neurology can be attributed European scientists such as Golgi\, Brown-Séquard\, and Romberg. The EAN is confident that the scientific contributions of European experts today will  continue to shape the field of neurology. \nThe overarching theme of the 2022 EAN congress is “Getting Evidence Into Practice”. Topics will include: Which clinical trial designs best inform practice? What evidence informs the use of diagnostic tests? Are guidelines a useful tool for improving outcomes? How do we get guidelines applied and implemented? These questions are timely and relevant\, and we are excited to hear from selected experts from neurology and other disciplines. As with every year\, leading specialists will share the most recent state-of-the-art studies and the newest developments in neurology\, and we invite all participants ask questions in the live Q&A sessions. \nFind more information here!
URL:https://www.braincouncil.eu/event/8th-congress-of-the-european-academy-of-neurology/
LOCATION:Vienna\, Austria
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20220623T140000
DTEND;TZID=UTC:20220623T160000
DTSTAMP:20260415T002030
CREATED:20220622T092244Z
LAST-MODIFIED:20220622T092808Z
UID:37643-1655992800-1656000000@www.braincouncil.eu
SUMMARY:Preparing Europe for Novel Psychedelic-Assisted Therapies: Launch of PAREA
DESCRIPTION:We all know the feeling of helplessness when we are unable to help people – often our loved ones – who are affected by mental health conditions\, addictions or neurological ailments\, including chronic pain. We know that mental healthcare is in crisis and we don’t have enough options to truly help many people in need. While it is true that there are many people who wouldn’t be here if it weren’t for antidepressants\, there are also millions who are on them and continue to struggle or experience serious side effects. Moreover\, the global expenditure on mental health amounts to a mere 2% of general expenditure (WHO\, 2021) and only a minority of people with mental health conditions in Europe receive treatment. We have a long way to go in improving mental health care\, and in achieving the relevant UN Sustainable Development Goals by 2030. \nAgainst this backdrop\, psychedelic-assisted therapies (PAT) show a promise of being a potent new class of treatments for mental\, neurological and substance use disorders\, as suggested by the rapidly growing\, rigorous\, and compelling body of research. \nIn 2021 alone\, ground-breaking findings were published in journals such as Lancet\, Nature and New England Journal of Medicine. Top tier US universities like NY University\, Johns Hopkins and the University of California are following the example of Imperial College London in the UK\, which in 2019 became the first to establish a centre dedicated to the study of psychedelic compounds. \nDuring 2017 – 2019\, the US FDA granted Breakthrough Therapy designation to PAT for three trials investigating psilocybin for depression and MDMA for PTSD. \nThe fundamental therapeutic benefit of PAT comes from the combination of psychedelic medicine and therapy. The drug is a catalyst for treatment\, not a treatment in itself. Patients report that they get something deeply meaningful out of the altered consciousness – a sense of unity\, of connection. Therapy allows them to incorporate that into an enduring shift in identity and to build a better self. In other words\, psychedelics’ novel therapeutic value stems from their role as enhancements to a psychotherapeutic process\, grounded in a relationship-centred approach\, that views mental health through a biopsychosocial lens. \nThe renaissance of research into the neuroscience and therapeutic applications of PAT represents one of the most promising and important initiatives in brain science and neuropsychopharmacology in recent times\, especially given the huge unmet needs in the therapeutic areas that they promise to treat. \nAt the same time\, much has to be done in Europe to start accommodating those advances and to accelerate the safe and responsible integration of PAT into EU healthcare systems in the years to come. This work must start now. \nWith this in mind\, the Psychedelic Access and Research European Alliance – PAREA was born. We bring together 15 members\, including EU patient advocacy groups in the field of mental health\, neurology and chronic pain\, scientific associations – neuropsychopharmacologists and cancer societies\, psychedelic foundations\, as well as industry partners. \nWe will be launching this partnership on 23rd June\, 2pm – 4pm CEST. See agenda below: \nPAREA agenda
URL:https://www.braincouncil.eu/event/37643/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20220604T090000
DTEND;TZID=UTC:20220604T120000
DTSTAMP:20260415T002030
CREATED:20220328T133047Z
LAST-MODIFIED:20220425T104134Z
UID:35190-1654333200-1654344000@www.braincouncil.eu
SUMMARY:European Brain Research Area (EBRA) at the 8th European Psychiatric Association (EPA) Forum
DESCRIPTION:EBC\, as project coordinators\, will present the European Brain Research Area (EBRA) project at the upcoming 8th European Psychiatric Association (EPA) Forum (taking place at the upcoming European Congress on Psychiatry 2022)\, centred around “Mental Health Care and Research in Europe: From Bench to Bedside and Back”. The Forum will take place on Saturday\, 4 June 2022\, 9:00-12:00 CEST at the congress venue in Budapest\, Hungary. The project will be presented by EBC Executive Director\, Frédéric Destrebecq. \nThe EPA Forum traditionally precedes the official opening of the annual European Congress on Psychiatry and aims to bring together EPA members and Congress delegates with European organisations\, stakeholders and policy makers in the field of mental health and mental health care to present and discuss matters of European importance. This year’s programme will focus on the role of research and evidence-based policies to improve mental health care in the EU. In this regard\, the EBRA project achievements\, namely the recently released landscape analysis on brain research (mapping report) and upcoming Shared European Brain Research Agenda (SEBRA) will be presented.
URL:https://www.braincouncil.eu/event/ebra-at-the-8th-epa-forum/
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220604
DTEND;VALUE=DATE:20220608
DTSTAMP:20260415T002030
CREATED:20220429T121209Z
LAST-MODIFIED:20220429T121428Z
UID:36146-1654300800-1654646399@www.braincouncil.eu
SUMMARY:Autism Care Pathway in Europe | European Congress of Psychiatry
DESCRIPTION:The 30th European Congress of Psychiatry\, organised by the largest association of psychiatrists in Europe\, will take place virtually on 4-7 June 2022. \nEBC looks forward to presenting the case study on autism spectrum disorder (ASD) as part of the Value of Treatment (VOT) project: \nBackground: Autism is a lifelong complex neurodevelopmental condition that affects brain development and behaviour with significant consequences for everyday life.  Despite its personal\, familial\, and societal impact\, Europe-wide harmonised guidelines are still lacking for early detection\, diagnosis\, and intervention\, leading to an overall unsatisfactory autistic person and carer journey. ​  \nMethods:  The care pathway for autistic children and adolescents was analysed in Italy\, Spain and the United Kingdom (UK) from the perspective of carers\, the autistic community\, and professionals in order to identify major barriers (treatment gaps) preventing carers from receiving information\, support\, and timely screening/diagnosis and intervention. ​  \nResults: Across all three countries\, analysis of the current care pathway showed: long waits from the time carers raised their first concerns about a child’s development and/or behaviour until screening and confirmed diagnosis; delayed or no access to intervention once a diagnosis was confirmed; limited information about autism and how to access early detection services; and deficient support for families throughout the journey. ​  \nConclusions: These findings call for policy harmonisation in Europe to shorten long wait times for diagnosis and intervention and therefore\, improve autistic people and their families’ journey experience and quality of life. 
URL:https://www.braincouncil.eu/event/autism-care-pathway-in-europe-european-congress-of-psychiatry/
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220604
DTEND;VALUE=DATE:20220608
DTSTAMP:20260415T002030
CREATED:20220425T101931Z
LAST-MODIFIED:20220429T121423Z
UID:36029-1654300800-1654646399@www.braincouncil.eu
SUMMARY:Value of Treatment Symposium on Mental Health | 30th European Congress of Psychiatry
DESCRIPTION:Recent studies underscore the severity of the mental health challenges children and adolescents face that can lead to high disability. There are numerous unmet needs along the care pathways\, although effective early detection and interventions exist. Navigating the mental health services system is often complex for families\, due to fragmented or disrupted services. \nThe Value of Treatment for Brain Disorders (VOT) is a health economics and outcomes research project coordinated by the European Brain Council. The second round (VOT2) on new therapeutic areas (anorexia nervosa\, autism spectrum disorder and major depressive disorder) was launched in 2019. This semester will be an important milestone in terms of case study results dissemination. The study looked at early intervention and explored the benefits of improved detection\, continuity of care and treatment\, and collaborative care patterns (also addressing mental health problems with comorbid medical conditions) on outcomes to patients and costs. Case studies which combine a care pathway analysis followed by an economic evaluation were conducted with the support of Academic Partners\, applying empirical evidence from different European countries.  \nThe European Brain Council (EBC) and the European Psychiatric Association (EPA) will convene a meeting at the upcoming EPA Congress 2022 to address challenges especially from the health economics perspective. Study results from VOT2 case studies on anorexia nervosa\, autism spectrum disorder and major depressive disorder\, will be showcased. In this symposium\, we report the findings of the groups of the Value of Treatment initiative and contextualise these by highlighting the limitations of existing economic models; the gaps in data availability; current research to address these gaps as well as directions for future research that will improve our ability to make the economic case for investment as well as our understanding of the patient experience and journey. 
URL:https://www.braincouncil.eu/event/value-of-treatment-symposium-on-mental-health-30th-european-congress-of-psychiatry/
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220604
DTEND;VALUE=DATE:20220608
DTSTAMP:20260415T002030
CREATED:20211115T143529Z
LAST-MODIFIED:20220630T104116Z
UID:32485-1654300800-1654646399@www.braincouncil.eu
SUMMARY:30th European Congress of Psychiatry
DESCRIPTION:  \nThe 30th European Congress of Psychiatry\, organised by the largest association of psychiatrists in Europe\, took place virtually on 4-7 June 2022. \nLinking Clinical Practice and Research for Better Mental Health Care in Europe. This was the guiding motto for the next edition of the EPA Congress. \nAn opportunity to engage with state-of-the-art clinical tools\, to expand the frontiers of research\, explore innovative ideas for mental health care and prevention with a community of global professionals and stakeholders in the field of psychiatry and mental health care. \nEBC was delighted to present: \n\nEuropean Brain Research Area (EBRA) at the 8th EPA Forum\nValue of Treatment (VOT) Symposium on Mental Health\nAutism Care Pathway in Europe\n\nFind more information about the EPA Congress here!
URL:https://www.braincouncil.eu/event/30th-european-congress-of-psychiatry/
LOCATION:Budapest\, Hungary
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20220512T140000
DTEND;TZID=UTC:20220512T163000
DTSTAMP:20260415T002030
CREATED:20220427T134537Z
LAST-MODIFIED:20220427T134537Z
UID:36086-1652364000-1652373000@www.braincouncil.eu
SUMMARY:Patient involvement in Brain Health: Safeguarding the future of Brain Health for patients
DESCRIPTION:In recent months\, discussions on brain health have much focused on how to bring brain research and brain health on the European agenda. Patient organisations have also been very active in bringing their views to the discussion. However\, we increasingly find that in relation to research in brain health and innovation\, patient involvement has not been not optimally represented and relatively little impact on patient care and diagnosis can be seen. \nThe patient community needs precision medicine\, in prevention and diagnosis\, of brain diseases. Neuroscience\, neurology and psychiatry must more closely align and transform their framework as the field of oncology has done. \nThree leading European patient organizations in the field\, Alzheimer Europe\, the European Federation of Neurological Alliances (EFNA) and GAMIAN-Europe\, have come together to organise a meeting that will underline to the brain health community why engaging patients in the discussion on brain health is crucial. \nThe meeting will present a call for action in anticipation of a possible brain health summit and – later – a brain health partnership. We will emphasise the importance of engaging the patient community in the discussions on brain health\, with the overall goal of bringing people from the entire community together\, outlining what our organisations hope to achieve\, and most of all raising awareness of this important matter. \nIn order to safeguard the future of brain health it is: \n\n\n\n\n\n\n\n\n\n\nEssential to systematically align all agendas in order to work towards agreed upon commitments to the brain health agenda. \nImperative that all stakeholders ensure that the priorities\, needs and expertise of all those living with Brain Health disorders are considered and included. \nImportant to make sure research is intrinsically connected to reality \n\n\n\n\n\n\n\n\n\nRegister here
URL:https://www.braincouncil.eu/event/patient-involvement-in-brain-health-safeguarding-the-future-of-brain-health-for-patients/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20220510T100000
DTEND;TZID=UTC:20220510T160000
DTSTAMP:20260415T002030
CREATED:20220502T080912Z
LAST-MODIFIED:20220502T080912Z
UID:36219-1652176800-1652198400@www.braincouncil.eu
SUMMARY:8th Academy of National Brain Councils
DESCRIPTION:The 8th Academy of National Brain Councils will be held on 10th May 2022 in Brussels\, Belgium\, hosted at the Representation of the Free State of Bavaria to the European Union. \nThis year’s Academy will host the launch of the German Brain Plan\, led by the German Brain Council\, including a presentation on how the plan was formed and plans for its implementation. Furthermore\, updates and sharing of good practices in developing National Brain Plans will be presented by the Norwegian\, German\, Belgian\, Dutch and Polish Brain Councils. \nThe meeting will take place from 10:00-16:00\, including both closed and public programmes\, also including presentations on the future plans of the European Commission for brain disorders: the EU “HealthierTogether”Initiative and the presentation of EBC’s Strategy and National Brain Plans to decision-makers. \nFor more information\, please contact events@braincouncil.eu 
URL:https://www.braincouncil.eu/event/8th-academy-of-national-brain-councils/
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220504
DTEND;VALUE=DATE:20220507
DTSTAMP:20260415T002030
CREATED:20211116T142438Z
LAST-MODIFIED:20211116T142608Z
UID:32611-1651622400-1651881599@www.braincouncil.eu
SUMMARY:8th Annual European Stroke Organisation Conference
DESCRIPTION:  \nThe 8th European Stroke Organisation Conference (ESOC 2022) will take place 4-6 May 2022 in Lyon\, France as a hybrid event. \nESOC is Europe’s leading forum\, and indeed a leading forum worldwide\, for advances in research and clinical care of patients with cerebrovascular diseases. ESOC 2022 will live up to its expectation\, and present to you a packed\, high quality scientific programme including  major clinical trials\, state-of-the-art seminars\, educational workshops\, scientific communications of the latest research\, and debates about current controversies. \nThe European Stroke Organisation’s mission is to reduce the burden of Stroke and to erase existing inequalities in stroke care in Europe. We firmly believe that together – through science\, education and research\, as well as networking and harmonizing how stroke is treated – this aim can be reached. \nESO acts as the Voice of Stroke in Europe and combines 43 organisations as well as over 2\,000 individual members. Over 5\,000 participants attend our conference and benefit from first-hand information about the latest breaking news and the newest ESO guidelines. ESOC also presents the perfect stepping-stone for young (and established) career professionals. \nVisit the conference website for more information!
URL:https://www.braincouncil.eu/event/8th-annual-european-stroke-organisation-conference/
LOCATION:Lyon\, France
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20220501T102000
DTEND;TZID=UTC:20220501T104000
DTSTAMP:20260415T002030
CREATED:20220330T114515Z
LAST-MODIFIED:20220330T114515Z
UID:35253-1651400400-1651401600@www.braincouncil.eu
SUMMARY:Value of Treatment (VOT) case study on phenylketonuria (PKU) | EPNS Congress 2022
DESCRIPTION:  \nThe Value of Treatment for Brain Disorders (VOT) is a health economics and outcomes research project coordinated by the European Brain Council (EBC). According to the World Health Organization\, disorders of the brain affect up to one in three people worldwide.  \nA second round (VOT2) on new therapeutic areas was launched in 2019\, focusing on The Value of Early Diagnosis and Coordinated Care for Rare Diseases (Ataxia\, Dystonia and Phenylketonuria); and The Value of Early Intervention and Continuity of Care for Mental Disorders (Anorexia Nervosa\, Autism Spectrum Disorder and Major Depressive Disorder). \nProf. Anita MacDonald will present a case study on phenylketonuria (PKU) at the 14th European Paediatric Neurology Society Congress in Glasgow\, on 1 May (10:20 – 10:40).
URL:https://www.braincouncil.eu/event/value-of-treatment-vot-case-study-on-phenylketonuria-pku-epns-congress-2022/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20220430T102000
DTEND;TZID=UTC:20220430T104000
DTSTAMP:20260415T002030
CREATED:20220330T113927Z
LAST-MODIFIED:20220330T113943Z
UID:35246-1651314000-1651315200@www.braincouncil.eu
SUMMARY:Value of Treatment (VOT) case study on ataxia | EPNS Congress 2022
DESCRIPTION:  \nThe Value of Treatment for Brain Disorders (VOT) is a health economics and outcomes research project coordinated by the European Brain Council (EBC). According to the World Health Organization\, disorders of the brain affect up to one in three people worldwide.  \nA second round (VOT2) on new therapeutic areas was launched in 2019\, focusing on The Value of Early Diagnosis and Coordinated Care for Rare Diseases (Ataxia\, Dystonia and Phenylketonuria); and The Value of Early Intervention and Continuity of Care for Mental Disorders (Anorexia Nervosa\, Autism Spectrum Disorder and Major Depressive Disorder). \nProf. Paola Giunti will present a case study on ataxia at the 14th European Paediatric Neurology Society Congress in Glasgow\, on 30 April (10:20 – 10:40).
URL:https://www.braincouncil.eu/event/value-of-treatment-vot-case-study-on-ataxia-epns-congress-2022/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20220429T140500
DTEND;TZID=UTC:20220429T155000
DTSTAMP:20260415T002030
CREATED:20220114T110915Z
LAST-MODIFIED:20220330T115028Z
UID:33648-1651241100-1651247400@www.braincouncil.eu
SUMMARY:Promoting Child Neurology in Europe | EPNS Congress 2022
DESCRIPTION:  \nOn 29 April 2022\, Joke Jaarsma\, Treasurer of the European Brain Council\, will hold a presentation on “Promoting child neurology in Europe” in the context of the 14th Congress of the European Paediatric Neurology Society (EPNS) in Glasgow. \nThe EPNS Congress provides an opportunity to learn about the latest developments in the rapidly evolving field of child neurology\, including basic science\, diagnostic methods\, and novel treatments. You can network with colleagues and industry partners all focused on delivering the best possible care for children with neurological disorders. \nFor more information\, please visit: https://epns-congress.com/
URL:https://www.braincouncil.eu/event/how-ebc-can-promote-child-neurology-in-europe/
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220429
DTEND;VALUE=DATE:20220501
DTSTAMP:20260415T002030
CREATED:20220317T092031Z
LAST-MODIFIED:20220427T123503Z
UID:34862-1651190400-1651363199@www.braincouncil.eu
SUMMARY:EMSP Annual Conference 2022: ‘’A Holistic Approach for Personalised MS Care’’
DESCRIPTION:The EMSP Annual Conference 2022 will take place on 29-30 April 2022 in hybrid format\, virtually and in person in Madrid\, Spain. \nThe theme of this year’s conference is ”A Holistic Approach for Personalised MS Care”. The personalised care model seeks to deliver whole-population approaches to support people of all ages and their carers to manage their physical and mental health and well-being\, build community resilience\, and make informed decisions and choices when their health changes. \nBy bringing the MS societies\, the patient communities\, healthcare professionals\, researchers\, and policy decision makers together on a European level\, the conference will aim at improving the understanding of the latest development in the field of personalised healthcare for people with MS\, sharing knowledge and expertise\, identifying good practices across Europe and cross-sectors. \nThe programme is built around 3 pillars: \n\nEmpowering people affected by MS to make informed choices by learning about latest research developments and the latest digital support tools\nSocial inclusion\, the Impact of the social environment and participation in society on physical and mental health\nBuilding community resilience\n\nEBC is delighted to be invited as a contributor this year\, with EBC Executive Director\, Frédéric Destrebecq\, to take part in the session “MS in Europe: the value of integrated and personalized health and social care approaches” on the 29th of April\, from 12:00 to 12:30. \nGet your free virtual ticket here!
URL:https://www.braincouncil.eu/event/emsp-annual-conference-2022-a-holistic-approach-for-personalised-ms-care/
LOCATION:Madrid
END:VEVENT
END:VCALENDAR